Watanabe S, Furuya N, Nakamura A, Shiihara J, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Eur J Cancer 2024;197:113469.
PMID: 38061214